153 related articles for article (PubMed ID: 26824884)
1. Efficacy of a new once daily hydromorphone formulation in comparison with twice daily administration in chronic pain: a randomized, double-blind, cross-over study.
Nold GE; Maritz MA; Schwittay A; Schumann C; Rey H
Curr Med Res Opin; 2016 May; 32(5):869-77. PubMed ID: 26824884
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of the first oxycodone once daily prolonged release tablet in moderate to severe chronic pain: a randomized, double-blind, multicenter, cross-over, non-inferiority study to investigate efficacy and safety in comparison with an established oxycodone twice daily prolonged release tablet.
Lux EA; Janecki M; Maritz MA
Curr Med Res Opin; 2014 Nov; 30(11):2365-75. PubMed ID: 25050592
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
Hale M; Tudor IC; Khanna S; Thipphawong J
Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
[TBL] [Abstract][Full Text] [Related]
4. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
[TBL] [Abstract][Full Text] [Related]
5. Dose equivalence of immediate-release hydromorphone and once-daily osmotic-controlled extended-release hydromorphone: a randomized, double-blind trial incorporating a measure of assay sensitivity.
Cruciani RA; Katz N; Portenoy RK
J Pain; 2012 Apr; 13(4):379-89. PubMed ID: 22424912
[TBL] [Abstract][Full Text] [Related]
6. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain.
Hagen NA; Babul N
Cancer; 1997 Apr; 79(7):1428-37. PubMed ID: 9083166
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study.
Yu S; Shen W; Yu L; Hou Y; Han J; Richards HM
J Pain; 2014 Aug; 15(8):835-44. PubMed ID: 24846822
[TBL] [Abstract][Full Text] [Related]
8. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain.
Palangio M; Northfelt DW; Portenoy RK; Brookoff D; Doyle RT; Dornseif BE; Damask MC
J Pain Symptom Manage; 2002 May; 23(5):355-68. PubMed ID: 12007754
[TBL] [Abstract][Full Text] [Related]
9. Comparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer pain.
Hays H; Hagen N; Thirlwell M; Dhaliwal H; Babul N; Harsanyi Z; Darke AC
Cancer; 1994 Sep; 74(6):1808-16. PubMed ID: 7521784
[TBL] [Abstract][Full Text] [Related]
10. A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain.
Binsfeld H; Szczepanski L; Waechter S; Richarz U; Sabatowski R
Pain Pract; 2010; 10(5):404-15. PubMed ID: 20384968
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients.
Inoue S; Saito Y; Tsuneto S; Aruga E; Takahashi H; Uemori M
Jpn J Clin Oncol; 2018 Jun; 48(6):542-547. PubMed ID: 29659913
[TBL] [Abstract][Full Text] [Related]
12. Safety and Tolerability of Once-Daily OROS(®) hydromorphone extended-release in opioid-tolerant adults with moderate-to-severe chronic cancer and noncancer pain: pooled analysis of 11 clinical studies.
Nalamachu SR; Kutch M; Hale ME
J Pain Symptom Manage; 2012 Dec; 44(6):852-65. PubMed ID: 22795050
[TBL] [Abstract][Full Text] [Related]
13. Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain.
Richarz U; Waechter S; Sabatowski R; Szczepanski L; Binsfeld H
Pain Pract; 2013 Jan; 13(1):30-40. PubMed ID: 22510252
[TBL] [Abstract][Full Text] [Related]
14. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain.
Hale M; Khan A; Kutch M; Li S
Curr Med Res Opin; 2010 Jun; 26(6):1505-18. PubMed ID: 20429852
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled trials.
Grosset AB; Roberts MS; Woodson ME; Shi M; Swanton RE; Reder RF; Buckley BJ
J Pain Symptom Manage; 2005 Jun; 29(6):584-94. PubMed ID: 15963867
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127).
Wallace M; Skowronski R; Khanna S; Tudor IC; Thipphawong J
Curr Med Res Opin; 2007 May; 23(5):981-9. PubMed ID: 17519065
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study.
Ridgway D; Sopata M; Burneckis A; Jespersen L; Andersen C
J Pain Symptom Manage; 2010 Apr; 39(4):712-20. PubMed ID: 20413058
[TBL] [Abstract][Full Text] [Related]
18. Open-label study to evaluate the efficacy and safety of extended-release hydromorphone in patients with chronic neuropathic pain.
Nalamachu S; Ruck D; Nalamasu R; Fasbinder S; Bansal R
J Opioid Manag; 2013; 9(1):43-9. PubMed ID: 23709303
[TBL] [Abstract][Full Text] [Related]
19. Comparative effects of morning vs. evening dosing of extended-release hydromorphone on sleep physiology in patients with low back pain: a pilot study.
Webster LR; Smith MD; Mackin S; Iverson M
Pain Med; 2015 Mar; 16(3):460-71. PubMed ID: 25279807
[TBL] [Abstract][Full Text] [Related]
20. Hydromorphone extended release for neuropathic and non-neuropathic/nociceptive chronic low back pain: a post hoc analysis of data from a randomized, multicenter, double-blind, placebo-controlled clinical trial.
Nalamachu S; Hale M; Khan A
J Opioid Manag; 2014; 10(5):311-22. PubMed ID: 25350473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]